0. Is this significant because the FDA was institutionally-(/culturally-)against phage therapies because the Soviets went that way rather than antibiotics? Does

0. Is this significant because the FDA was institutionally-(/culturally-)against phage therapies because the Soviets went that way rather than antibiotics? Does anyone know how much of a hurdle that is still? 1. Isn't it the case that resistances to phages should be perhaps (an) order(s)-of-magnitude less likely for prokaryotes and fungi to evolve resistances compared to static compounds like antibotics/antimycotics because phages are probably the most abundant "almost life" parasitizing other microbes in the wild? 2. Are we any closer to computational molecular-level engineering of custom antigens against any particular pathogen? 3. Although probably tiny, is there a risk of horizontal gene transfer between phages and other pathogens?